A novel podocyte gene, semaphorin 3G, protects glomerular podocyte from lipopolysaccharide-induced inflammation. 2016

Ryoichi Ishibashi, and Minoru Takemoto, and Yoshihiro Akimoto, and Takahiro Ishikawa, and Peng He, and Yoshiro Maezawa, and Kenichi Sakamoto, and Yuya Tsurutani, and Shintaro Ide, and Kana Ide, and Harukiyo Kawamura, and Kazuki Kobayashi, and Hirotake Tokuyama, and Karl Tryggvason, and Christer Betsholtz, and Koutaro Yokote
Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Kidney diseases including diabetic nephropathy have become huge medical problems, although its precise mechanisms are still far from understood. In order to increase our knowledge about the patho-physiology of kidney, we have previously identified >300 kidney glomerulus-enriched transcripts through large-scale sequencing and microarray profiling of the mouse glomerular transcriptome. One of the glomerulus-specific transcripts identified was semaphorin 3G (Sema3G) which belongs to the semaphorin family. The aim of this study was to analyze both the in vivo and in vitro functions of Sema3G in the kidney. Sema3G was expressed in glomerular podocytes. Although Sema3G knockout mice did not show obvious glomerular defects, ultrastructural analyses revealed partially aberrant podocyte foot processes structures. When these mice were injected with lipopolysaccharide to induce acute inflammation or streptozotocin to induce diabetes, the lack of Sema3G resulted in increased albuminuria. The lack of Sema3G in podocytes also enhanced the expression of inflammatory cytokines including chemokine ligand 2 and interleukin 6. On the other hand, the presence of Sema3G attenuated their expression through the inhibition of lipopolysaccharide-induced Toll like receptor 4 signaling. Taken together, our results surmise that the Sema3G protein is secreted by podocytes and protects podocytes from inflammatory kidney diseases and diabetic nephropathy.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000419 Albuminuria The presence of albumin in the urine, an indicator of KIDNEY DISEASES. Albuminurias
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013311 Streptozocin An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals. Streptozotocin,2-Deoxy-2-((methylnitrosoamino)carbonyl)amino-D-glucose,Streptozotocine,Zanosar

Related Publications

Ryoichi Ishibashi, and Minoru Takemoto, and Yoshihiro Akimoto, and Takahiro Ishikawa, and Peng He, and Yoshiro Maezawa, and Kenichi Sakamoto, and Yuya Tsurutani, and Shintaro Ide, and Kana Ide, and Harukiyo Kawamura, and Kazuki Kobayashi, and Hirotake Tokuyama, and Karl Tryggvason, and Christer Betsholtz, and Koutaro Yokote
August 2022, Nature reviews. Rheumatology,
Ryoichi Ishibashi, and Minoru Takemoto, and Yoshihiro Akimoto, and Takahiro Ishikawa, and Peng He, and Yoshiro Maezawa, and Kenichi Sakamoto, and Yuya Tsurutani, and Shintaro Ide, and Kana Ide, and Harukiyo Kawamura, and Kazuki Kobayashi, and Hirotake Tokuyama, and Karl Tryggvason, and Christer Betsholtz, and Koutaro Yokote
May 2017, Experimental and therapeutic medicine,
Ryoichi Ishibashi, and Minoru Takemoto, and Yoshihiro Akimoto, and Takahiro Ishikawa, and Peng He, and Yoshiro Maezawa, and Kenichi Sakamoto, and Yuya Tsurutani, and Shintaro Ide, and Kana Ide, and Harukiyo Kawamura, and Kazuki Kobayashi, and Hirotake Tokuyama, and Karl Tryggvason, and Christer Betsholtz, and Koutaro Yokote
January 2011, Arteriosclerosis, thrombosis, and vascular biology,
Ryoichi Ishibashi, and Minoru Takemoto, and Yoshihiro Akimoto, and Takahiro Ishikawa, and Peng He, and Yoshiro Maezawa, and Kenichi Sakamoto, and Yuya Tsurutani, and Shintaro Ide, and Kana Ide, and Harukiyo Kawamura, and Kazuki Kobayashi, and Hirotake Tokuyama, and Karl Tryggvason, and Christer Betsholtz, and Koutaro Yokote
October 2013, The American journal of pathology,
Ryoichi Ishibashi, and Minoru Takemoto, and Yoshihiro Akimoto, and Takahiro Ishikawa, and Peng He, and Yoshiro Maezawa, and Kenichi Sakamoto, and Yuya Tsurutani, and Shintaro Ide, and Kana Ide, and Harukiyo Kawamura, and Kazuki Kobayashi, and Hirotake Tokuyama, and Karl Tryggvason, and Christer Betsholtz, and Koutaro Yokote
October 2019, Kidney international,
Ryoichi Ishibashi, and Minoru Takemoto, and Yoshihiro Akimoto, and Takahiro Ishikawa, and Peng He, and Yoshiro Maezawa, and Kenichi Sakamoto, and Yuya Tsurutani, and Shintaro Ide, and Kana Ide, and Harukiyo Kawamura, and Kazuki Kobayashi, and Hirotake Tokuyama, and Karl Tryggvason, and Christer Betsholtz, and Koutaro Yokote
January 2020, Journal of immunology (Baltimore, Md. : 1950),
Ryoichi Ishibashi, and Minoru Takemoto, and Yoshihiro Akimoto, and Takahiro Ishikawa, and Peng He, and Yoshiro Maezawa, and Kenichi Sakamoto, and Yuya Tsurutani, and Shintaro Ide, and Kana Ide, and Harukiyo Kawamura, and Kazuki Kobayashi, and Hirotake Tokuyama, and Karl Tryggvason, and Christer Betsholtz, and Koutaro Yokote
July 2012, CNS neuroscience & therapeutics,
Ryoichi Ishibashi, and Minoru Takemoto, and Yoshihiro Akimoto, and Takahiro Ishikawa, and Peng He, and Yoshiro Maezawa, and Kenichi Sakamoto, and Yuya Tsurutani, and Shintaro Ide, and Kana Ide, and Harukiyo Kawamura, and Kazuki Kobayashi, and Hirotake Tokuyama, and Karl Tryggvason, and Christer Betsholtz, and Koutaro Yokote
January 2012, Evidence-based complementary and alternative medicine : eCAM,
Ryoichi Ishibashi, and Minoru Takemoto, and Yoshihiro Akimoto, and Takahiro Ishikawa, and Peng He, and Yoshiro Maezawa, and Kenichi Sakamoto, and Yuya Tsurutani, and Shintaro Ide, and Kana Ide, and Harukiyo Kawamura, and Kazuki Kobayashi, and Hirotake Tokuyama, and Karl Tryggvason, and Christer Betsholtz, and Koutaro Yokote
April 2024, American journal of physiology. Renal physiology,
Ryoichi Ishibashi, and Minoru Takemoto, and Yoshihiro Akimoto, and Takahiro Ishikawa, and Peng He, and Yoshiro Maezawa, and Kenichi Sakamoto, and Yuya Tsurutani, and Shintaro Ide, and Kana Ide, and Harukiyo Kawamura, and Kazuki Kobayashi, and Hirotake Tokuyama, and Karl Tryggvason, and Christer Betsholtz, and Koutaro Yokote
May 2019, Journal of medicinal chemistry,
Copied contents to your clipboard!